AL137 lead anti-Aβ antibody enters Phase I trials
Neurodegeneration-focused company ALEC is advancing its blood-brain barrier platform. Its lead anti-Aβ antibody AL137 has entered Phase I trials, while additional siRNA and enzyme therapies are progressing toward the clinic.
A neurodegeneration-focused company is moving its proprietary blood-brain barrier platform forward, with lead anti-Aβ antibody AL137 now in phase I trials. The platform’s unique epitope is said to support high brain penetration and reduced… Additional siRNA and enzyme therapies are also advancing toward the clinic.